AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2870810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg/day
Number of subjects: 244
Study 2870810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 100 mg/day
Number of subjects: 244
Study 2870810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 2870810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus Bevantolol 400 mg/day
Number of subjects: 244
Study 2870810 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (Hydrochlorothiazide + Bevantolol)
Number of subjects: 244
Study 2870810 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 244
Study 31045433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum during exercise
Number of subjects: 22
Study 29595563 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet noninvasive ventilation
Number of subjects: 83
Study 29595563 — intervention group
Group type: COMPARATOR
Intervention: Facemask noninvasive ventilation
Number of subjects: 83
Study 29595563 — intervention group
Group type: COMPARATOR
Intervention: ICU-acquired weakness
Number of subjects: 83
Study 26111953 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFRI treatment
Number of subjects: 85
Study 25653802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser treatment for 20 sessions of 20 minutes
Number of subjects: 120
Study 25653802 — intervention group
Group type: COMPARATOR
Intervention: Control group (same instrument but off)
Number of subjects: 120
Study 25653802 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser treatment
Number of subjects: 120
Study 22634184 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 30 mg QD + Open-label optimized background therapy (OBT)
Number of subjects: 857
Study 22634184 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 30 mg QD + OBT
Number of subjects: 857
Study 22634184 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Open-label optimized background therapy (OBT)
Number of subjects: 857
Study 22634184 — intervention group
Group type: COMPARATOR
Intervention: Placebo + OBT
Number of subjects: 857
Study 19907299 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-G standard PPV
Number of subjects: 60
Study 19907299 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-G transconjunctival sutureless vitrectomy (TSV)
Number of subjects: 60
Study 19907299 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 20-G and 25-G groups
Number of subjects: 60
Study 18631166 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic storage with acidified additive solution (AS) at pH 6.5, rejuvenated at 7 weeks of storage
Number of subjects: 8
Study 18631166 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic storage with acidified additive solution (AS) at pH 6.5, rejuvenated at 11 weeks of storage
Number of subjects: 8
Study 18631166 — intervention group
Group type: COMPARATOR
Intervention: Aerobic storage
Number of subjects: 8
Study 18631166 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic or neutral AS
Number of subjects: 8
Study 18631166 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral or basic pH AS
Number of subjects: 8
Study 18631166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold rejuvenation during anaerobic storage
Number of subjects: 8
Study 16144170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular administration of rt-PA (3 mg every 24 hours)
Number of subjects: 21
Study 16144170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular administration of rt-PA
Number of subjects: 21
Study 12361993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar support used daily for the first week and on LBP days for the following 6 months
Number of subjects: 59
Study 12361993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar support
Number of subjects: 59
Study 10462164 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal flexibility-plus-aerobic exercise
Number of subjects: 210
Study 10462164 — intervention group
Group type: COMPARATOR
Intervention: Aerobic-only exercise
Number of subjects: 210
Study 10462164 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 210
Study 7892144 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube
Number of subjects: 18
Study 7892144 — intervention group
Group type: COMPARATOR
Intervention: No NG tube
Number of subjects: 18
Study 2623306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyntic cell vagotomy with simple closure
Number of subjects: 180
Study 2623306 — intervention group
Group type: COMPARATOR
Intervention: Simple closure alone
Number of subjects: 180
Study 2623306 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180
Study 356240 — intervention group
Group type: EXPERIMENTAL
Intervention: Proquazone (3x300 mg/day)
Number of subjects: 36
Study 356240 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (2x250 mg plus one placebo capsule/day)
Number of subjects: 36
Study 30428474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg bid for 3 months
Number of subjects: 5
Study 30428474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg bid combined with lactulose 30-60 mL daily for 3 months
Number of subjects: 5
Study 30428474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin therapy with and without lactulose
Number of subjects: 5
Study 30428474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin therapy
Number of subjects: 5
Study 30218387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite (HDM) allergen extract
Number of subjects: 40
Study 30218387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26358331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold forceps polypectomy (CFP) with narrow-band imaging (NBI) evaluation
Number of subjects: 146
Study 26358331 — intervention group
Group type: COMPARATOR
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 146
Study 26358331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold forceps polypectomy (CFP) with NBI evaluation
Number of subjects: 146
Study 26358331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold forceps polypectomy (CFP)
Number of subjects: 146
Study 24421304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic exercise intervention (EXIMS) with usual care
Number of subjects: 120
Study 24421304 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 120
Study 23295594 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian Cardioprotective Diet Program (weekly sessions with dietitians)
Number of subjects: 0
Study 23295594 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary therapy (Group B - weekly sessions with dietitian)
Number of subjects: 0
Study 23295594 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary therapy (Group C - monthly sessions with dietitian)
Number of subjects: 0
Study 19531257 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-meal rye bread (150 g)
Number of subjects: 10
Study 19531257 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread (150 g)
Number of subjects: 10
Study 17218551 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided therapy
Number of subjects: 208
Study 17218551 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 208
Study 15538680 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated neoprene splint (PFN)
Number of subjects: 25
Study 15538680 — intervention group
Group type: COMPARATOR
Intervention: Custom-made thermoplastic short opponens splint (CMT)
Number of subjects: 25
Study 11808763 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum containing 0.19 mg of CPP-ACP
Number of subjects: 30
Study 11808763 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum containing 10.0 mg of CPP-ACP
Number of subjects: 30
Study 11808763 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum containing 18.8 mg of CPP-ACP
Number of subjects: 30
Study 11808763 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum containing 56.4 mg of CPP-ACP
Number of subjects: 30
Study 11808763 — intervention group
Group type: COMPARATOR
Intervention: Control gum (sorbitol- or xylitol-based without CPP-ACP)
Number of subjects: 30
Study 9777110 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg/day
Number of subjects: 23
Study 9777110 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg/day
Number of subjects: 23
Study 9777110 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day
Number of subjects: 23
Study 9777110 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study 7832578 — intervention group
Group type: COMPARATOR
Intervention: 0 g elemental calcium (control)
Number of subjects: 24
Study 7832578 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g elemental calcium
Number of subjects: 24
Study 7832578 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g elemental calcium
Number of subjects: 24
Study 3683094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg, sublingual)
Number of subjects: 6
Study 29731413 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2700
Study 29731413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2700
Study 29731413 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride and Placebo
Number of subjects: 2700
Study 27172664 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin wound induction gel
Number of subjects: 48
Study 27172664 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine
Number of subjects: 48
Study 25083559 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 43
Study 25083559 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Muscle Vibration (LMV)
Number of subjects: 43
Study 25083559 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 21607791 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavicle Score (CS)
Number of subjects: 172
Study 21607791 — intervention group
Group type: COMPARATOR
Intervention: Control group (45 healthy volunteers)
Number of subjects: 172
Study 20950433 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 104
Study 18058457 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 110
Study 18058457 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 110
Study 15679765 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless pH capsule
Number of subjects: 50
Study 11864667 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with induction late in labor (greater than or equal to 6 cm)
Number of subjects: 1862
Study 11864667 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia with induction between 3 and 5 cm
Number of subjects: 1862
Study 11864667 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with an interval of greater than or equal to 360 minutes between induction and full dilatation
Number of subjects: 1862
Study 11864667 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with height less than 160 cm
Number of subjects: 1862
Study 11864667 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with prepregnancy weight greater than 65 kg
Number of subjects: 1862
Study 11864667 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged greater than or equal to 35 years
Number of subjects: 1862
Study 11864667 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with gestational age greater than or equal to 41 weeks
Number of subjects: 1862
Study 11864667 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal station above +2 at full dilatation
Number of subjects: 1862
Study 11864667 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fetal position
Number of subjects: 1862
Study 7717486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (0.85 mg.kg‐1)
Number of subjects: 52
Study 7717486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.7 micrograms.kg‐1)
Number of subjects: 52
Study 7717486 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (1 mg.kg‐1)
Number of subjects: 52
Study 7717486 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 52
Study 1972833 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UV-B phototherapy (Philips TL‐01)
Number of subjects: 10
Study 1972833 — intervention group
Group type: COMPARATOR
Intervention: PUVA photochemotherapy (oral 8‐MOP followed by UV‐A from Philips TL‐09)
Number of subjects: 10
Study 381921 — intervention group
Group type: EXPERIMENTAL
Intervention: Piadar lotion, applied 2 to 3 times daily for four weeks
Number of subjects: 20
Study 381921 — intervention group
Group type: COMPARATOR
Intervention: Tolnaftate solution, applied 2 to 3 times daily for four weeks
Number of subjects: 20
Study 31912799 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab (FOLFIRI/Cet)
Number of subjects: 199
Study 31196899 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint-flavoured chewing gum for 15 minutes
Number of subjects: 272
Study 31196899 — intervention group
Group type: COMPARATOR
Intervention: 4 mg intravenous ondansetron
Number of subjects: 272
Study 28777421 — intervention group
Group type: EXPERIMENTAL
Intervention: RG‐IV (retractable guidewire IV catheter)
Number of subjects: 218
Study 28777421 — intervention group
Group type: COMPARATOR
Intervention: C‐IV (conventional IV catheter)
Number of subjects: 218
Study 28777421 — intervention group
Group type: EXPERIMENTAL
Intervention: RG‐IV
Number of subjects: 218
Study 28777421 — intervention group
Group type: COMPARATOR
Intervention: C‐IV
Number of subjects: 218
Study 28956529 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (1 mg/kg)
Number of subjects: 72
Study 28956529 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid microspheres loaded with flurbiprofen
Number of subjects: 72
Study 24092829 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phosphate diet (1800 mg/d) for 6 days
Number of subjects: 26
Study 21843970 — intervention group
Group type: EXPERIMENTAL
Intervention: LH < P25
Number of subjects: 1764
Study 21843970 — intervention group
Group type: COMPARATOR
Intervention: LH ≥ P25
Number of subjects: 1764
Study 21843970 — intervention group
Group type: EXPERIMENTAL
Intervention: LH > P75
Number of subjects: 1764
Study 21843970 — intervention group
Group type: COMPARATOR
Intervention: LH ≤ P75
Number of subjects: 1764
Study 19307106 — intervention group
Group type: EXPERIMENTAL
Intervention: AZI-ER 2g
Number of subjects: 71
Study 19307106 — intervention group
Group type: COMPARATOR
Intervention: AZI-IR 500 mg
Number of subjects: 71
Study 17702589 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusion starting in the operating theatre (Group OT)
Number of subjects: 45
Study 17702589 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan infusion starting in the ICU (Group ICU)
Number of subjects: 45
Study 15080773 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg ghrelin (acylated form)
Number of subjects: 18
Study 15080773 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg ghrelin (acylated form)
Number of subjects: 18
Study 15080773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mannitol)
Number of subjects: 18
Study 15080773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin administration (both doses)
Number of subjects: 18
Study 11343562 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of milrinone (5 microg/kg/min)
Number of subjects: 20
Study 11343562 — intervention group
Group type: COMPARATOR
Intervention: Treatment without milrinone
Number of subjects: 20
Study 9806580 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta2 glycoprotein I IgM antibody and antinuclear antibody
Number of subjects: 360
Study 9806580 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibodies
Number of subjects: 360
Study 9806580 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity for autoantibodies tested
Number of subjects: 360
Study 7853124 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing alone (brush)
Number of subjects: 125
Study 7853124 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing plus chlorhexidine 0.12% rinse 2x/day (CHX)
Number of subjects: 125
Study 7853124 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing plus water irrigation 1x/day (irr+H2O)
Number of subjects: 125
Study 7853124 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing plus chlorhexidine 0.04% irrigation 1x/day (irr+CHX)
Number of subjects: 125
Study 7853124 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation groups (irr+H2O and irr+CHX)
Number of subjects: 125
Study 2527829 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 10
Study 2527829 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10
Study 1096388 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly regimen of rifampicin 1200 mg plus ethambutol 50 mg/kg body weight (E1R1)
Number of subjects: 247
Study 1096388 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly regimen of rifampicin 1200 mg plus ethambutol 50 mg/kg body weight (E2R2)
Number of subjects: 247
Study 1096388 — intervention group
Group type: COMPARATOR
Intervention: Initial inpatient phase of rifampicin 600 mg and ethambutol 25 mg/kg daily for 12 weeks
Number of subjects: 247
Study 31661663 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional reduced‐exertion, high‐intensity interval training (TREHIT)
Number of subjects: 36
Study 31661663 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened‐sprint REHIT (SSREHIT)
Number of subjects: 36
Study 31661663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint continuous training (SCT)
Number of subjects: 36
Study 31237610 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing acupressure
Number of subjects: 67
Study 31237610 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating acupressure
Number of subjects: 67
Study 31237610 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study 28051986 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-Guided (WFG) PRK
Number of subjects: 54
Study 28051986 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-Optimized (WFO) PRK
Number of subjects: 54
Study 26562379 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study 26562379 — intervention group
Group type: COMPARATOR
Intervention: Wound Gel
Number of subjects: 0
Study 26562379 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care plus Wound Gel (SOC + gel)
Number of subjects: 0
Study 24289208 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1553
Study 21111078 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating dose teriparatide (20 μg daily for 6 months, then 30 μg daily for 6 months, and then 40 μg daily for 6 months)
Number of subjects: 52
Study 21111078 — intervention group
Group type: COMPARATOR
Intervention: Constant dose teriparatide (30 μg daily for 18 months)
Number of subjects: 52
Study 19224196 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1963
Study 19224196 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1963
Study 19224196 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance
Number of subjects: 1963
Study 16273395 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) stimulation with dopaminergic medication on
Number of subjects: 39
Study 16273395 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) stimulation with dopaminergic medication off
Number of subjects: 39
Study 16273395 — intervention group
Group type: COMPARATOR
Intervention: Bilateral subthalamic nucleus (STN) stimulation off with low medication (usual dose)
Number of subjects: 39
Study 16273395 — intervention group
Group type: COMPARATOR
Intervention: Bilateral subthalamic nucleus (STN) stimulation off with high medication (suprathreshold dose)
Number of subjects: 39
Study 16273395 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) stimulation on with low medication (usual dose)
Number of subjects: 39
Study 15270795 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 2838
Study 15270795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study 11390722 — intervention group
Group type: EXPERIMENTAL
Intervention: HF1 (on-line predilution haemofiltration)
Number of subjects: 24
Study 11390722 — intervention group
Group type: EXPERIMENTAL
Intervention: HF2 (as phase I)
Number of subjects: 24
Study 11390722 — intervention group
Group type: COMPARATOR
Intervention: HD (high-flux haemodialysis)
Number of subjects: 24
Study 11390722 — intervention group
Group type: EXPERIMENTAL
Intervention: HF (both HF1 and HF2)
Number of subjects: 24
Study 11390722 — intervention group
Group type: EXPERIMENTAL
Intervention: HF2
Number of subjects: 24
Study 9497707 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 12
Study 8088206 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal infusion with Mitomycin‐C (MMC) and 5‐Fluorouracil (5‐FU) starting immediately after operation
Number of subjects: 533
Study 8088206 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 533
Study 11039044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.5% zinc citrate and 0.2% Triclosan
Number of subjects: 39
Study 11039044 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 39
Study 30826617 — intervention group
Group type: EXPERIMENTAL
Intervention: Spark-ignition emissions (GAS)
Number of subjects: 0
Study 30826617 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel (DIE)
Number of subjects: 0
Study 30826617 — intervention group
Group type: EXPERIMENTAL
Intervention: Road dust (RD)
Number of subjects: 0
Study 30826617 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual oil (RO)
Number of subjects: 0